Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6644694 | 0.76 | MAPT (0.38) | MAPTKDM4EALDH1A1HTTMAPK1 | |
| SCHEMBL6646364 | 0.74 | KDM4E (0.39) | MAPTKDM4EALDH1A1HTTMAPK1 | |
| SCHEMBL1121904 | 0.66 | POLB (0.45) | MAPT | |
| SCHEMBL6647834 | 0.65 | MAPK1 (0.56) | MAPTKDM4EALDH1A1HTTMAPK1 | |
| SCHEMBL7011778 | 0.65 | KEAP1 (0.35) | MAPTKDM4EALDH1A1 | |
| SCHEMBL7014156 | 0.65 | HSD17B10 (0.35) | MAPTKDM4E | |
| SCHEMBL8593509 | 0.64 | TSHR (0.44) | MAPTKDM4EALDH1A1HTT | |
| SCHEMBL4636735 | 0.63 | CES2 (0.57) | MAPTALDH1A1 | |
| SCHEMBL10585954 | 0.63 | CES2 (0.57) | MAPTALDH1A1 | |
| SCHEMBL5314369 | 0.63 | CES2 (0.57) | MAPTKDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401830-A2 | QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | WARNER-LAMBERT COMPANY | 2003-06-19 | — | — | US | disclosed |
| WO-2002102793-A2 | QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | ABCC1, RPS6KA1, SIGMAR1 | MAPT 4486/4885KDM4E 1886/4885ALDH1A1 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.